Divestiture Services

Maximize the value of every exit. Every time.

Whether you’re selling a complete company, carving out a division or preparing for a public offering, A&M can provide the necessary divestiture support to maximize exit value and allow management to focus on maintaining business performance.

Careful assessment to evaluate your IPO readiness and ensure alignment

We provide a hands-on approach, working closely with management and its other advisers to help transition your business from a private company to a public company.

Alvarez & Marsal (A&M) - Divestiture Services: Sell-side Support

Sell-side and vendor due diligence: In-depth analysis to unlock potential value

We work with your company and its management team to maximize exit value and prepare for a robust sale process.

Global Valuation Services

Companies, private equity and hedge funds, and investors deal with transactional information that is recorded at fair value, which often differs from cost. Understanding this difference and its impact on your business is crucial. A&M gets to the core value and what it means for you.

Thought Leadership

Digital Deception: Fighting Fraud in the Era of Emerging Technology

August 26, 2025

Davin Teo and Henry Chambers, Managing Directors and Co-leaders of Disputes and Investigations Asia wrote an article on digital deception for the Hong Kong Chartered Governance Institute’s CGj August 2025 issue.

Thought Leadership

Unlocking Federal Real Estate: Efficiency, Partnerships, and the Path Ahead

August 26, 2025

Our Managing Directors, Tom Scott and Paul Firth, join George Guszcza, President & CEO of the National Institute of Building Sciences, on The GovNavigators Show to discuss trends, challenges, and opportunities shaping the future of federal real estate.

Thought Leadership

DOJ and HHS collaborate to enhance False Claims Act prosecution

August 25, 2025

In a recent article for Westlaw Today, Managing Directors Jenelle Beavers and Donald Lochabay explore the U.S. government’s new collaboration and enforcement priorities around the False Claims Act (FCA).

Thought Leadership

Next-Generation Antibodies: A New Era in Immuno-Oncology

August 25, 2025

As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.